2026 Q1 -tulosraportti
34 päivää sitten
‧44 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 11.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 päivä sittenShorted shares have increased recently by 4 million. This means that 22% of the shares are shorted. Quite sure that's why they managed to stop the positive trend that had started. The stock has been heavily shorted for a long time and has not been able to play out its true value (around 10$ if you calculate the average of all price targets). Those of you who have not informed your platform where the shares are held in endowment policies or similar, please inform them that your shares should NOT be available for lending. They will have much more difficulty manipulating the price if fewer shares are available.
·1 päivä sittenRetail accounts with margin – Here is an often underestimated source. When retail investors at Nordnet, Robinhood, Schwab, Fidelity, Interactive Brokers etc. trade in a margin account, they typically have agreements that allow the broker to lend out their shares. The broker keeps most of the fee. For a stock like ABCL with a large retail share, this can be significant. My estimate: ~50-70 % of retail margin shares in ABCL are actually lent out. That gives us ~15-22 million lent shares from retail margin. Do as I do and call Nordnet and tell them that your shares should not be part of the stock lending program that Nordnet is involved in.- ·7.6.AbCellera strengthens its board – why this is strategically important On June 5, 2026, AbCellera announced that Dr. Victor Sandor is joining as an independent board member. For a clinical-stage biotechnology company, the composition of the board is crucial. This is where long-term strategic choices are made regarding clinical strategy, regulatory processes, and how research will be transformed into approved medicines. Dr. Sandor brings deep clinical and regulatory experience. He has held leading roles at Array BioPharma, Incyte, Biogen, and AstraZeneca, and has been instrumental in taking several drugs all the way to market approval. This type of expertise is particularly valuable when a company, like AbCellera, transitions from primarily being a technology and collaboration platform to running its own drug programs in the clinic. Commercially, the appointment strengthens AbCellera's credibility and execution capability. Experience in how clinical studies are designed, how dialogue with authorities is conducted, and how risks are managed in late development phases increases the likelihood of well-founded decisions. It can also make the company more attractive for partnerships with larger pharmaceutical companies, where the board's expertise is often considered. Looking ahead, there are several clear bright spots. AbCellera has ongoing clinical programs, where ABCL635 in women's health is in Phase 2 and addresses a large medical need with significant market potential. At the same time, the pipeline is being further developed in immunology and oncology, alongside investments in organization, R&D, and manufacturing capacity. The company also has a strong financial position, which provides freedom to operate and pursue its strategy without short-term pressure. In summary, Dr. Sandor's entry signals that AbCellera is preparing for the next stage of development. It is less about short-term market reactions and more about building a company with the right leadership to successfully bring innovative medicines from clinic to patients in the long term.
- ·4.6.When finance meets science: Analysis of Andrew Booth's presentation at Jefferies Today, CFO Andrew Booth took the stage at the Jefferies Global Healthcare Conference in New York. For those of us following AbCellera closely, this was a very interesting presentation, not least because of the dynamic of the company's CFO acting as a spearhead to communicate scientific progress. The contrast that adds weight: Finance meets science When a CFO delves deeply into scientific programs like ABCL635 (their program against endocrine diseases), it adds extra weight to the narrative. Booth is ultimately the one who controls capital allocation. When he radiates a "very positive" attitude towards the internal pipeline, it shows that management is putting money exactly where they see the greatest probability of success. He combines financial coolness with scientific understanding. Why ABCL635 is "The Big Story" It's no coincidence that Booth places enormous focus on ABCL635. The program is the ultimate symbol of AbCellera's strategic transformation. We have moved from a "partner-only" model to proving that we can drive our own complex discoveries through the early clinical phase. This is where the real revaluation of the company will take place. Booth as a "Straight Shooter" – A strategic asset That Booth is perceived as both smart and direct is a massive asset for AbCellera. His style creates value on several levels: -Intellectual honesty: He is positive about the future prospects, but careful to highlight the remaining scientific risks. He doesn't sell a dream, which increases credibility. -Delivery and stability: The presentation was "100% consistent" with the latest quarterly report. The market abhors surprises; investors want to see the plan followed to the letter. -Proactive risk management: By openly talking about the risks, he "vaccinates" the stock against future setbacks. The market can price in the uncertainty factors in advance. -Trust capital: A CFO who avoids hiding uncertainties builds invaluable trust capital for future financings and strategic agreements. Market reaction: A strong endorsement Although the reactions from the audience in the conference room itself were difficult to gauge, the stock market spoke a clear language during the day (June 4, 2026). The ABCL stock rose significantly, from an opening of approximately 5.55 USD to just over 6.63 USD by American lunchtime – an increase of almost 16 %. The high trading volume and sharp price surge in connection with the presentation clearly indicate that investors received the management's update and the Phase 1 data very well. Conclusion Today's presentation reinforces the image of AbCellera having grown up. We are witnessing the transition from being a "promising technology platform" to becoming a methodical and disciplined drug developer. Internal discipline is high, they do not stray from the established line, and the plan remains firm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
34 päivää sitten
‧44 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenShorted shares have increased recently by 4 million. This means that 22% of the shares are shorted. Quite sure that's why they managed to stop the positive trend that had started. The stock has been heavily shorted for a long time and has not been able to play out its true value (around 10$ if you calculate the average of all price targets). Those of you who have not informed your platform where the shares are held in endowment policies or similar, please inform them that your shares should NOT be available for lending. They will have much more difficulty manipulating the price if fewer shares are available.·1 päivä sittenRetail accounts with margin – Here is an often underestimated source. When retail investors at Nordnet, Robinhood, Schwab, Fidelity, Interactive Brokers etc. trade in a margin account, they typically have agreements that allow the broker to lend out their shares. The broker keeps most of the fee. For a stock like ABCL with a large retail share, this can be significant. My estimate: ~50-70 % of retail margin shares in ABCL are actually lent out. That gives us ~15-22 million lent shares from retail margin. Do as I do and call Nordnet and tell them that your shares should not be part of the stock lending program that Nordnet is involved in.
- ·7.6.AbCellera strengthens its board – why this is strategically important On June 5, 2026, AbCellera announced that Dr. Victor Sandor is joining as an independent board member. For a clinical-stage biotechnology company, the composition of the board is crucial. This is where long-term strategic choices are made regarding clinical strategy, regulatory processes, and how research will be transformed into approved medicines. Dr. Sandor brings deep clinical and regulatory experience. He has held leading roles at Array BioPharma, Incyte, Biogen, and AstraZeneca, and has been instrumental in taking several drugs all the way to market approval. This type of expertise is particularly valuable when a company, like AbCellera, transitions from primarily being a technology and collaboration platform to running its own drug programs in the clinic. Commercially, the appointment strengthens AbCellera's credibility and execution capability. Experience in how clinical studies are designed, how dialogue with authorities is conducted, and how risks are managed in late development phases increases the likelihood of well-founded decisions. It can also make the company more attractive for partnerships with larger pharmaceutical companies, where the board's expertise is often considered. Looking ahead, there are several clear bright spots. AbCellera has ongoing clinical programs, where ABCL635 in women's health is in Phase 2 and addresses a large medical need with significant market potential. At the same time, the pipeline is being further developed in immunology and oncology, alongside investments in organization, R&D, and manufacturing capacity. The company also has a strong financial position, which provides freedom to operate and pursue its strategy without short-term pressure. In summary, Dr. Sandor's entry signals that AbCellera is preparing for the next stage of development. It is less about short-term market reactions and more about building a company with the right leadership to successfully bring innovative medicines from clinic to patients in the long term.
- ·4.6.When finance meets science: Analysis of Andrew Booth's presentation at Jefferies Today, CFO Andrew Booth took the stage at the Jefferies Global Healthcare Conference in New York. For those of us following AbCellera closely, this was a very interesting presentation, not least because of the dynamic of the company's CFO acting as a spearhead to communicate scientific progress. The contrast that adds weight: Finance meets science When a CFO delves deeply into scientific programs like ABCL635 (their program against endocrine diseases), it adds extra weight to the narrative. Booth is ultimately the one who controls capital allocation. When he radiates a "very positive" attitude towards the internal pipeline, it shows that management is putting money exactly where they see the greatest probability of success. He combines financial coolness with scientific understanding. Why ABCL635 is "The Big Story" It's no coincidence that Booth places enormous focus on ABCL635. The program is the ultimate symbol of AbCellera's strategic transformation. We have moved from a "partner-only" model to proving that we can drive our own complex discoveries through the early clinical phase. This is where the real revaluation of the company will take place. Booth as a "Straight Shooter" – A strategic asset That Booth is perceived as both smart and direct is a massive asset for AbCellera. His style creates value on several levels: -Intellectual honesty: He is positive about the future prospects, but careful to highlight the remaining scientific risks. He doesn't sell a dream, which increases credibility. -Delivery and stability: The presentation was "100% consistent" with the latest quarterly report. The market abhors surprises; investors want to see the plan followed to the letter. -Proactive risk management: By openly talking about the risks, he "vaccinates" the stock against future setbacks. The market can price in the uncertainty factors in advance. -Trust capital: A CFO who avoids hiding uncertainties builds invaluable trust capital for future financings and strategic agreements. Market reaction: A strong endorsement Although the reactions from the audience in the conference room itself were difficult to gauge, the stock market spoke a clear language during the day (June 4, 2026). The ABCL stock rose significantly, from an opening of approximately 5.55 USD to just over 6.63 USD by American lunchtime – an increase of almost 16 %. The high trading volume and sharp price surge in connection with the presentation clearly indicate that investors received the management's update and the Phase 1 data very well. Conclusion Today's presentation reinforces the image of AbCellera having grown up. We are witnessing the transition from being a "promising technology platform" to becoming a methodical and disciplined drug developer. Internal discipline is high, they do not stray from the established line, and the plan remains firm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 11.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
34 päivää sitten
‧44 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 11.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenShorted shares have increased recently by 4 million. This means that 22% of the shares are shorted. Quite sure that's why they managed to stop the positive trend that had started. The stock has been heavily shorted for a long time and has not been able to play out its true value (around 10$ if you calculate the average of all price targets). Those of you who have not informed your platform where the shares are held in endowment policies or similar, please inform them that your shares should NOT be available for lending. They will have much more difficulty manipulating the price if fewer shares are available.·1 päivä sittenRetail accounts with margin – Here is an often underestimated source. When retail investors at Nordnet, Robinhood, Schwab, Fidelity, Interactive Brokers etc. trade in a margin account, they typically have agreements that allow the broker to lend out their shares. The broker keeps most of the fee. For a stock like ABCL with a large retail share, this can be significant. My estimate: ~50-70 % of retail margin shares in ABCL are actually lent out. That gives us ~15-22 million lent shares from retail margin. Do as I do and call Nordnet and tell them that your shares should not be part of the stock lending program that Nordnet is involved in.
- ·7.6.AbCellera strengthens its board – why this is strategically important On June 5, 2026, AbCellera announced that Dr. Victor Sandor is joining as an independent board member. For a clinical-stage biotechnology company, the composition of the board is crucial. This is where long-term strategic choices are made regarding clinical strategy, regulatory processes, and how research will be transformed into approved medicines. Dr. Sandor brings deep clinical and regulatory experience. He has held leading roles at Array BioPharma, Incyte, Biogen, and AstraZeneca, and has been instrumental in taking several drugs all the way to market approval. This type of expertise is particularly valuable when a company, like AbCellera, transitions from primarily being a technology and collaboration platform to running its own drug programs in the clinic. Commercially, the appointment strengthens AbCellera's credibility and execution capability. Experience in how clinical studies are designed, how dialogue with authorities is conducted, and how risks are managed in late development phases increases the likelihood of well-founded decisions. It can also make the company more attractive for partnerships with larger pharmaceutical companies, where the board's expertise is often considered. Looking ahead, there are several clear bright spots. AbCellera has ongoing clinical programs, where ABCL635 in women's health is in Phase 2 and addresses a large medical need with significant market potential. At the same time, the pipeline is being further developed in immunology and oncology, alongside investments in organization, R&D, and manufacturing capacity. The company also has a strong financial position, which provides freedom to operate and pursue its strategy without short-term pressure. In summary, Dr. Sandor's entry signals that AbCellera is preparing for the next stage of development. It is less about short-term market reactions and more about building a company with the right leadership to successfully bring innovative medicines from clinic to patients in the long term.
- ·4.6.When finance meets science: Analysis of Andrew Booth's presentation at Jefferies Today, CFO Andrew Booth took the stage at the Jefferies Global Healthcare Conference in New York. For those of us following AbCellera closely, this was a very interesting presentation, not least because of the dynamic of the company's CFO acting as a spearhead to communicate scientific progress. The contrast that adds weight: Finance meets science When a CFO delves deeply into scientific programs like ABCL635 (their program against endocrine diseases), it adds extra weight to the narrative. Booth is ultimately the one who controls capital allocation. When he radiates a "very positive" attitude towards the internal pipeline, it shows that management is putting money exactly where they see the greatest probability of success. He combines financial coolness with scientific understanding. Why ABCL635 is "The Big Story" It's no coincidence that Booth places enormous focus on ABCL635. The program is the ultimate symbol of AbCellera's strategic transformation. We have moved from a "partner-only" model to proving that we can drive our own complex discoveries through the early clinical phase. This is where the real revaluation of the company will take place. Booth as a "Straight Shooter" – A strategic asset That Booth is perceived as both smart and direct is a massive asset for AbCellera. His style creates value on several levels: -Intellectual honesty: He is positive about the future prospects, but careful to highlight the remaining scientific risks. He doesn't sell a dream, which increases credibility. -Delivery and stability: The presentation was "100% consistent" with the latest quarterly report. The market abhors surprises; investors want to see the plan followed to the letter. -Proactive risk management: By openly talking about the risks, he "vaccinates" the stock against future setbacks. The market can price in the uncertainty factors in advance. -Trust capital: A CFO who avoids hiding uncertainties builds invaluable trust capital for future financings and strategic agreements. Market reaction: A strong endorsement Although the reactions from the audience in the conference room itself were difficult to gauge, the stock market spoke a clear language during the day (June 4, 2026). The ABCL stock rose significantly, from an opening of approximately 5.55 USD to just over 6.63 USD by American lunchtime – an increase of almost 16 %. The high trading volume and sharp price surge in connection with the presentation clearly indicate that investors received the management's update and the Phase 1 data very well. Conclusion Today's presentation reinforces the image of AbCellera having grown up. We are witnessing the transition from being a "promising technology platform" to becoming a methodical and disciplined drug developer. Internal discipline is high, they do not stray from the established line, and the plan remains firm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt